Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.

Baker JF, Mizelle KV, Saikali W, Moore PC, Kang HJ, Gruben D, Shelbaya A, Stockert L, O'Brien J

DOI: 10.1002/acr2.70109
Published: 2025 Nov
Container: ACR open rheumatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/acr2.70109,
  title = {Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.},
  author = {Baker JF and Mizelle KV and Saikali W and Moore PC and Kang HJ and Gruben D and Shelbaya A and Stockert L and O'Brien J},
  year = {2025},
  journal = {ACR open rheumatology},
  doi = {10.1002/acr2.70109},
  url = {https://doi.org/10.1002/acr2.70109}
}

RIS

TY  - JOUR
TI  - Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.
AU  - Baker JF
AU  - Mizelle KV
AU  - Saikali W
AU  - Moore PC
AU  - Kang HJ
AU  - Gruben D
AU  - Shelbaya A
AU  - Stockert L
AU  - O'Brien J
PY  - 2025
JO  - ACR open rheumatology
DO  - 10.1002/acr2.70109
UR  - https://doi.org/10.1002/acr2.70109
ER  -

APA

JF, B., KV, M., W, S., PC, M., HJ, K., D, G., A, S., L, S., & J, O. (2025). Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.. ACR open rheumatology. https://doi.org/10.1002/acr2.70109

Source records

pubmed · retrieved 2026-09-26T16:11:14.230Z